Advertisement.

CGEM Projected Dividend Yield

Cullinan Therapeutics Inc ( NASDAQ : CGEM )

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies.

21 YEAR PERFORMANCE RESULTS

CGEM Dividend History Detail
CGEM Dividend News
CGEM Competitors News

# of Shares: 0

Closing Price: 12.68

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000